Abseamed

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
21-08-2023

Ingredient activ:

epoetin alfa

Disponibil de la:

Medice Arzneimittel Pütter GmbH Co. KG

Codul ATC:

B03XA01

INN (nume internaţional):

epoetin alfa

Grupul Terapeutică:

Antianemic preparations

Zonă Terapeutică:

Anemia; Kidney Failure, Chronic; Cancer

Indicații terapeutice:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy).Abseamed can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (haemoglobin (Hb) 10-13 g/dl [6.2-8.1 mmol/l], no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).Abseamed can be used to reduce exposure to allogeneic blood transfusions in adult non iron deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with an expected blood loss of 900 to 1800 ml.

Rezumat produs:

Revision: 22

Statutul autorizaţiei:

Authorised

Data de autorizare:

2007-08-27

Prospect

                                75
B. PACKAGE LEAFLET
76
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ABSEAMED 1,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 2,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 3,000 IU/0.3 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 4,000 IU/0.4 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 5,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 6,000 IU/0.6 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 7,000 IU/0.7 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 8,000 IU/0.8 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 9,000 IU/0.9 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 10,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
ABSEAMED 20,000 IU/0.5 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 30,000 IU/0.75 ML SOLUTION FOR INJECTION IN A PRE-FILLED
SYRINGE
ABSEAMED 40,000 IU/1 ML SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE
Epoetin alfa
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Abseamed is and what it is used for
2.
What you need to know before you use Abseamed
3.
How to use Abseamed
4.
Possible side effects
5.
How to store Abseamed
6.
Contents of the pack and other information
1.
WHAT ABSEAMED IS AND WHAT IT IS USED FOR
Abseamed contains the active substance epoetin alfa, a protein that
stimulates the bone marrow to
produce more red blood cells which carry haemoglobin (a substance that
transports oxygen). Epoe
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled
syringe
Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled
syringe
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled
syringe
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled
syringe
Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled
syringe
Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 0.5 mL contains 1,000 international units (IU)
corresponding to 8.4 micrograms
epoetin alfa. *
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Each mL of solution contains 2,000 IU of epoetin alfa
*
corresponding to 16.8 micrograms per mL
A pre-filled syringe of 1 mL contains 2,000 international units (IU)
corresponding to 16.8 micrograms
epoetin alfa. *
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*
corresponding to 84.0 micrograms per mL
A pre-filled syringe of 0.3 mL contains 3,000 international units (IU)
corresponding
to 25.2 micrograms epoetin alfa. *
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled
syringe
Each mL of solution contains 10,000 IU of epoetin alfa
*

                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului bulgară 21-08-2023
Raport public de evaluare Raport public de evaluare bulgară 03-10-2018
Prospect Prospect spaniolă 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului spaniolă 21-08-2023
Raport public de evaluare Raport public de evaluare spaniolă 03-10-2018
Prospect Prospect cehă 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului cehă 21-08-2023
Raport public de evaluare Raport public de evaluare cehă 03-10-2018
Prospect Prospect daneză 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului daneză 21-08-2023
Raport public de evaluare Raport public de evaluare daneză 03-10-2018
Prospect Prospect germană 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului germană 21-08-2023
Raport public de evaluare Raport public de evaluare germană 03-10-2018
Prospect Prospect estoniană 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului estoniană 21-08-2023
Raport public de evaluare Raport public de evaluare estoniană 03-10-2018
Prospect Prospect greacă 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului greacă 21-08-2023
Raport public de evaluare Raport public de evaluare greacă 03-10-2018
Prospect Prospect franceză 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului franceză 21-08-2023
Raport public de evaluare Raport public de evaluare franceză 03-10-2018
Prospect Prospect italiană 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului italiană 21-08-2023
Raport public de evaluare Raport public de evaluare italiană 03-10-2018
Prospect Prospect letonă 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului letonă 21-08-2023
Raport public de evaluare Raport public de evaluare letonă 03-10-2018
Prospect Prospect lituaniană 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului lituaniană 21-08-2023
Raport public de evaluare Raport public de evaluare lituaniană 03-10-2018
Prospect Prospect maghiară 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului maghiară 21-08-2023
Raport public de evaluare Raport public de evaluare maghiară 03-10-2018
Prospect Prospect malteză 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului malteză 21-08-2023
Raport public de evaluare Raport public de evaluare malteză 03-10-2018
Prospect Prospect olandeză 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului olandeză 21-08-2023
Raport public de evaluare Raport public de evaluare olandeză 03-10-2018
Prospect Prospect poloneză 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului poloneză 21-08-2023
Raport public de evaluare Raport public de evaluare poloneză 03-10-2018
Prospect Prospect portugheză 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului portugheză 21-08-2023
Raport public de evaluare Raport public de evaluare portugheză 03-10-2018
Prospect Prospect română 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului română 21-08-2023
Raport public de evaluare Raport public de evaluare română 03-10-2018
Prospect Prospect slovacă 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului slovacă 21-08-2023
Raport public de evaluare Raport public de evaluare slovacă 03-10-2018
Prospect Prospect slovenă 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului slovenă 21-08-2023
Raport public de evaluare Raport public de evaluare slovenă 03-10-2018
Prospect Prospect finlandeză 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului finlandeză 21-08-2023
Raport public de evaluare Raport public de evaluare finlandeză 03-10-2018
Prospect Prospect suedeză 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului suedeză 21-08-2023
Raport public de evaluare Raport public de evaluare suedeză 03-10-2018
Prospect Prospect norvegiană 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului norvegiană 21-08-2023
Prospect Prospect islandeză 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului islandeză 21-08-2023
Prospect Prospect croată 21-08-2023
Caracteristicilor produsului Caracteristicilor produsului croată 21-08-2023
Raport public de evaluare Raport public de evaluare croată 03-10-2018

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor